Arsenic Trioxide-Induced Cardiotoxicity Risk Assessment Predictor

Assess the risk probability of cardiotoxic adverse events in APL patients during arsenic trioxide treatment

Personal Parameters

Patient Input Information:

1. Inorganic arsenic (iAs, ng/mL)

2. Monomethylarsonic acid (MMA, ng/mL)

3. Dimethylarsenic acid (DMA, ng/mL)

4. Co-use of cardiotoxic drugs

Please scroll down to view the cardiotoxic drug combination table.

Risk of Cardiotoxicity Occurrence

Arsenic Metabolism Parameters

Arsenic metabolism parameter index calculation:

1. Total arsenic (tAs, ng/mL)

2. Primary methylation index (PMI)

3. Secondary methylation index (SMI)

4. Inorganic arsenic percentage (iAs%)

5. Monomethylarsonic acid percentage (MMA%)

6. Dimethylarsenic acid percentage (DMA%)

Please scroll down to view the arsenic metabolism parameter calculation formula.

Risk Factors

Abbreviations: CT_drug, co-use of cardiotoxic drugs; DMA_per, dimethylarsenic acid percentage; MMA_per, monomethylarsonic acid percentage; SMI, secondary methylation index; tAs, total arsenic.

Cardiotoxicity Risk Quantification

Interpretation:
The bar graph represents the quantitative risk of whether risk factors promote cardiotoxicity.
Bars extending to the right indicate factors that promote cardiotoxicity.
Bars extending to the left indicate factors that inhibit cardiotoxicity.
The values of bars represent the SHAP quantitative values of risk factors' influence on cardiotoxicity.

Co-use of Cardiotoxic Drugs

Arsenic Metabolism Parameter Definitions

Abbreviations: iAs, Inorganic Arsenic; MMA, monomethylarsonic Acid; DMA, dimethylarsinic Acid; tAs, Total Arsenic; PMI, primary Methylation Index; SMI, secondary Methylation Index; iAs%, inorganic Arsenic percentage; MMA%, monomethylarsonic Acid percentage; DMA%, dimethylarsinic Acid percentage.

Suggestions for Result

Introduction

Arsenic trioxide (ATO) stands as a highly effective chemotherapeutic agent for acute promyelocytic leukemia (APL). However, its clinical application is significantly challenged by cardiotoxicity. Adverse cardiac events occur with notable frequency and can lead to prolonged hospitalization or fatal outcomes. Effectively managing this balance between achieving superior efficacy and mitigating cardiac risks is paramount for improving patient survival and quality of life.
Our free online Arsenic Trioxide Cardiotoxicity Risk Predictor is developed to address this precise clinical need. It integrates data from authoritative clinical studies and real-world adverse event reports to provide users with a personalized, forward-looking risk assessment.

Abbreviations: XXXXX

Why Use the Risk Assessment Predictor for Arsenic Trioxide-Induced Cardiotoxicity?

a) Scientific Early Warning: The tool calculates a quantitative risk value by analyzing core risk factors such as arsenic metabolism parameters and the concurrent use of other cardiotoxic drugs. This provides a more objective and reliable assessment than subjective feelings.
b) Convenience and Efficiency: There is no need to make a medical appointment for a consultation. By simply filling out the online form for about one minute, you can receive a professional risk assessment report based on a large-data model.
c) Motivation for Action: A clear assessment result can effectively raise health awareness, motivating you to adopt a healthier lifestyle or proactively seek medical advice.
d) Dynamic Monitoring: You can regularly reassess (e.g., every six months or annually) to observe changes in your risk level after adjusting your lifestyle or receiving treatment, thereby tracking improvements in your health status.

How to Use This Online Assessment Tool?

a) Within the patient information input table, search the co-use medication table to indicate if you are taking any other drugs known to have cardiotoxic effects.
b) Refer to your most recent arsenic concentration test report and enter key arsenic metabolite indicators such as inorganic arsenic (iAs), monomethylarsonic acid (MMA), and dimethylarsinic acid (DMA).
c) Click the "Calculate Cardiotoxicity Induced by Arsenic Trioxide" button, and the system will generate your personalized risk assessment report in real-time.

Contents of the Assessment Report.

a) Risk Probability Diagnosis: It will show the probability of developing cardiotoxicity following treatment with arsenic trioxide, along with an interpretation of what this risk level means for you.
b) Analysis of Major Risk Factors: It will identify the factors contributing most significantly to your individual risk, helping you understand which aspects require closer monitoring.
c) Personalized Action Recommendations: It will provide targeted suggestions, including guidance on treatment plans and advice on when you should consult a doctor based on your specific risk assessment outcome.

Contact us: Haixin@hrmu.edu.cn
Address: Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Citation: XXXX.

Upload Your Data

Class represents to classify patients into high/low-risk groups based on whether the white blood cell count is greater than 10×10⁹ /L, according to the NCCN(2025) guideline.
Dose represents the arsenic trioxide treatment dosage per kilogram of body weight recommended for patients according to the NCCN(2025) guideline.
iAs represents inorganic arsenic concentration.
MMA represents monomethylarsonic acid concentration.
DMA represents dimethylarsenic acid concentration.

Download Template File